Dosage Forms of Palonosetron Hydrochloride Having Improved Stability and Bioavailability
First Claim
Patent Images
1. ) A soft gelatin capsule for oral administration comprising:
- a) a soft gelatin outer shell having an oxygen permeability of less than about 1.0×
10−
3 ml·
cm/(cm2·
24 hr. atm); and
b) a lipophilic liquid inner fill composition comprising;
i) greater than about 50 wt. % of one or more lipophilic components;
ii) from about 1 to about 20 wt. % of water miscibilized or homogenized in said one or more lipophilic components;
iii) from about 0.05 to about 2.0 mg. of palonosetron as palonosetron hydrochloride solubilized or dispersed in said water; and
iv) a surfactant.wherein said capsule exhibits pharmacokinetics when orally ingested in a fasted state that are bioequivalent to a formulation having greater than 95% absolute bioavailability, wherein bioequivalence is established by a 90% confidence interval for AUC which is between 80% and 125%.
1 Assignment
0 Petitions
Accused Products
Abstract
Provided are solid oral dosage forms of palonosetron hydrochloride, methods of using the dosage forms to treat emesis, and methods of making the dosage forms. The dosage forms have improved stability and bioavailability, and are preferably in the form of liquid filled capsules.
38 Citations
27 Claims
-
1. ) A soft gelatin capsule for oral administration comprising:
-
a) a soft gelatin outer shell having an oxygen permeability of less than about 1.0×
10−
3 ml·
cm/(cm2·
24 hr. atm); andb) a lipophilic liquid inner fill composition comprising; i) greater than about 50 wt. % of one or more lipophilic components; ii) from about 1 to about 20 wt. % of water miscibilized or homogenized in said one or more lipophilic components; iii) from about 0.05 to about 2.0 mg. of palonosetron as palonosetron hydrochloride solubilized or dispersed in said water; and iv) a surfactant. wherein said capsule exhibits pharmacokinetics when orally ingested in a fasted state that are bioequivalent to a formulation having greater than 95% absolute bioavailability, wherein bioequivalence is established by a 90% confidence interval for AUC which is between 80% and 125%. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
-
-
11. ) A liquid filled soft capsule dosage form for oral administration comprising:
-
a) an outer shell having a oxygen permeability of less than about 1.0×
10−
3 ml·
cm/(cm2·
24 hr. atm); andb) an inner fill composition comprising from about 0.05 to about 2.0 mg. of palonosetron or pharmaceutically acceptable salt thereof, wherein said palonosetron or pharmaceutically acceptable salt thereof comprises Cpd1 of a pharmaceutically acceptable salt thereof in an amount of less than 1.0 wt. % based on the weight of said palonosetron. wherein said inner fill composition comprises oxygen in an amount that mediates no more than about 3.0 wt. % oxidative degradation of said palonosetron or pharmaceutically acceptable salt thereof when said dosage form is stored three months or greater at 40°
C. and 75% RH. - View Dependent Claims (12, 13, 14, 15, 16, 17, 18)
-
-
19. ) A method of optimizing the bioavailability and stability of palonosetron in a palonosetron gelatin capsule comprising:
-
a) providing a soft gelatin outer shell having an oxygen permeability of less than about 1.0×
10−
3 ml·
cm/(cm2·
24 hr. atm); andb) preparing a fill composition by steps comprising; i) providing from about 0.05 to about 2.0 mg. of palonosetron as palonosetron hydrochloride wherein said palonosetron comprises Cpd1 in an amount of less than 3.0 wt. %; ii) dissolving or dispersing said palonosetron in water to form an aqueous premix; iii) mixing said aqueous premix with one or more lipophilic excipients, at a weight ratio of aqueous premix to lipophilic excipients of less than 30;
70, to form a miscible or homogenous lipophilic fill composition;iv) mixing a surfactant with said water, said aqueous premix, or said fill composition; and v) balancing the quantities of surfactant and water in said fill composition to facilitate the bioavailability of palonosetron from said gelatin capsule when orally ingested, and to minimize the degree of palonosetron degradation; and c) filling said outer shell with said fill composition. - View Dependent Claims (20, 21, 22)
-
-
23. ) A method of making a batch of palonosetron dosage forms having reduced quantities of impurities and oxygen mediated degradation products comprising:
-
a) mixing palonosetron hydrochloride and one or more pharmaceutically acceptable excipients to form a mixture; b) processing said mixture into a plurality of final dosage forms; and c) testing one or more of said final dosage forms for one or more palonosetron related compounds selected from Cpd1, Cpd2, and Cpd3, or the hydrochloride salt thereof. - View Dependent Claims (24, 25, 26, 27)
-
Specification